Home / Tag Archives: COVID-19 drug candidate priced at $2

Tag Archives: COVID-19 drug candidate priced at $2

COVID-19 drug candidate priced at $2,340 per patient


June 29, 2020

Gilead Sciences has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at $390. The price for U.S. private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient …

Read More »